These results argue that a RSK inhibitor would be beneficial in the treatment of ER + breast cancer but because RSK regulates many cellular processes a RSK inhibitor is also likely to be effective in cancers that are ER negative (ER-). The gene discussed is RPS6KA2; the disease is breast cancer.